What has the investment community excited about in 2022? - The Science Board | Canada News Media
Connect with us

Investment

What has the investment community excited about in 2022? – The Science Board

Published

 on


Cavazos began by telling ScienceBoard editor in chief, Samantha Black, PhD that 2021 was one of the worst years in biotech regarding investments since 2006.

“Some of the macro factors have been having an impact on the weakness… of the sector,” he said. “And then some company-specific events, particularly in Q4, really put a lot of pressure on the XDI biotech index. More broadly, we had a number of high-profile failures within year, which really have had an impact on investor sentiment.”

Video loading …

In spite of the tumultuous environment in 2021, it was still a record year for biopharma IPOs. Cavazos listed the following as indicators of success and enthusiasm from the investment community:

  • In the first half of the year alone there were over 75 initial public offerings (IPOs) in biopharma, realizing $14.7 billion
  • 80 crossovers deals (venture financings in which there is significant participation from investors that typically buy into publicly traded companies or IPOs)
  • Oncology, rare diseases and central nervous system diseases led in terms of dollars following into the market
  • Companies achieved over 80% of redemptions and 75 in the pipeline (the return of an investor’s principal on a fixed income security such as a bond, mutual fund or preferred stock)
  • Currently 80 special-purpose acquisition company (SPACs; 43 life sciences, $2 billion expiring in 2022)
  • Several large pharmaceutical companies have patent expirations coming up ($125 billion in lost revenue expected in 2022)
  • $200 billion in revenue coming from COVID-related sales

In 2022 investors expect a shift away from preclinical companies to companies with catalyst data that drives stock market prices, Cavazos commented. His team estimates 500 billion in cash available for acquisitions, share buybacks, and internal investments. They expect 2022 to be very active and hope to see an uptick deal-making, volume, and dollar value.

“And I think that’s where those markets are going, establishing proof of concept in smaller, more niche patient populations,” he explained. “And then leveraging that success and broadening it to much larger indications, more chronic indications with a larger percentage of the population.”

SVB Leerink is a healthcare-dedicated investment bank that has over 145 investment bankers focused on healthcare. They advise and work with biotech companies to help them raise equity investments for growth and innovation.

Do you have a unique perspective on your research related to biotech finance? Contact the editor today to learn more.

Related Reading

Top PE investments in biotools in 2021
2021 was an especially active year for private equity (PE) firms. According to PitchBook, the number of deals surged over 51% last year to top 8,600….

Copyright © 2022 scienceboard.net

Adblock test (Why?)



Source link

Continue Reading

Investment

Tesla shares soar more than 14% as Trump win is seen boosting Elon Musk’s electric vehicle company

Published

 on

 

NEW YORK (AP) — Shares of Tesla soared Wednesday as investors bet that the electric vehicle maker and its CEO Elon Musk will benefit from Donald Trump’s return to the White House.

Tesla stands to make significant gains under a Trump administration with the threat of diminished subsidies for alternative energy and electric vehicles doing the most harm to smaller competitors. Trump’s plans for extensive tariffs on Chinese imports make it less likely that Chinese EVs will be sold in bulk in the U.S. anytime soon.

“Tesla has the scale and scope that is unmatched,” said Wedbush analyst Dan Ives, in a note to investors. “This dynamic could give Musk and Tesla a clear competitive advantage in a non-EV subsidy environment, coupled by likely higher China tariffs that would continue to push away cheaper Chinese EV players.”

Tesla shares jumped 14.8% Wednesday while shares of rival electric vehicle makers tumbled. Nio, based in Shanghai, fell 5.3%. Shares of electric truck maker Rivian dropped 8.3% and Lucid Group fell 5.3%.

Tesla dominates sales of electric vehicles in the U.S, with 48.9% in market share through the middle of 2024, according to the U.S. Energy Information Administration.

Subsidies for clean energy are part of the Inflation Reduction Act, signed into law by President Joe Biden in 2022. It included tax credits for manufacturing, along with tax credits for consumers of electric vehicles.

Musk was one of Trump’s biggest donors, spending at least $119 million mobilizing Trump’s supporters to back the Republican nominee. He also pledged to give away $1 million a day to voters signing a petition for his political action committee.

In some ways, it has been a rocky year for Tesla, with sales and profit declining through the first half of the year. Profit did rise 17.3% in the third quarter.

The U.S. opened an investigation into the company’s “Full Self-Driving” system after reports of crashes in low-visibility conditions, including one that killed a pedestrian. The investigation covers roughly 2.4 million Teslas from the 2016 through 2024 model years.

And investors sent company shares tumbling last month after Tesla unveiled its long-awaited robotaxi at a Hollywood studio Thursday night, seeing not much progress at Tesla on autonomous vehicles while other companies have been making notable progress.

Tesla began selling the software, which is called “Full Self-Driving,” nine years ago. But there are doubts about its reliability.

The stock is now showing a 16.1% gain for the year after rising the past two days.

The Canadian Press. All rights reserved.

Source link

Continue Reading

Investment

S&P/TSX composite up more than 100 points, U.S. stock markets mixed

Published

 on

 

TORONTO – Canada’s main stock index was up more than 100 points in late-morning trading, helped by strength in base metal and utility stocks, while U.S. stock markets were mixed.

The S&P/TSX composite index was up 103.40 points at 24,542.48.

In New York, the Dow Jones industrial average was up 192.31 points at 42,932.73. The S&P 500 index was up 7.14 points at 5,822.40, while the Nasdaq composite was down 9.03 points at 18,306.56.

The Canadian dollar traded for 72.61 cents US compared with 72.44 cents US on Tuesday.

The November crude oil contract was down 71 cents at US$69.87 per barrel and the November natural gas contract was down eight cents at US$2.42 per mmBTU.

The December gold contract was up US$7.20 at US$2,686.10 an ounce and the December copper contract was up a penny at US$4.35 a pound.

This report by The Canadian Press was first published Oct. 16, 2024.

Companies in this story: (TSX:GSPTSE, TSX:CADUSD)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Economy

S&P/TSX up more than 200 points, U.S. markets also higher

Published

 on

 

TORONTO – Canada’s main stock index was up more than 200 points in late-morning trading, while U.S. stock markets were also headed higher.

The S&P/TSX composite index was up 205.86 points at 24,508.12.

In New York, the Dow Jones industrial average was up 336.62 points at 42,790.74. The S&P 500 index was up 34.19 points at 5,814.24, while the Nasdaq composite was up 60.27 points at 18.342.32.

The Canadian dollar traded for 72.61 cents US compared with 72.71 cents US on Thursday.

The November crude oil contract was down 15 cents at US$75.70 per barrel and the November natural gas contract was down two cents at US$2.65 per mmBTU.

The December gold contract was down US$29.60 at US$2,668.90 an ounce and the December copper contract was up four cents at US$4.47 a pound.

This report by The Canadian Press was first published Oct. 11, 2024.

Companies in this story: (TSX:GSPTSE, TSX:CADUSD)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Trending

Exit mobile version